tbuckley/cabot-search huggingface dataset:
Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial
Authors: Qian Chen, Chang Shu, Arian D Laurence, Yan Chen, Bao-Gang Peng, Zuo-Jun Zhen, Jian-Qiang Cai, Yi-Tao Ding, Le-Qun Li, Yu-Bao Zhang, Qi-Chang Zheng, Ge-Liang Xu, Bo Li, Wei-Ping Zhou, Shou-Wang Cai, Xi-Yan Wang, Hao Wen, Xin-Yu Peng, Xue-Wen Zhang, Chao-Liu Dai, Ping Bie, Bao-Cai Xing, Zhi-Ren Fu, Lian-Xin Liu, Yi Mu, Ling Zhang, Qi-Shun Zhang, Bin Jiang, Hai-Xin Qian, Yi-Jun Wang, Jing-Feng Liu, Xi-Hu Qin, Qiang Li, Ping Yin, Zhi-Wei Zhang, Xiao-Ping Chen
Journal: Gut (2018)

Objective There is little evidence that adjuvant therapy after radical surgical resection of hepatocellular carcinoma (HCC) improves recurrence-free survival (RFS) or overall survival (OS). We conducted a multicentre, randomised, controlled, phase IV trial evaluating the benefit of an aqueous extract of Trametes robinophila Murr (Huaier granule) to address this unmet need. Design and results A total of 1044 patients were randomised in 2:1 ratio to receive either Huaier or no further treatment (controls) for a maximum of 96 weeks. The primary endpoint was RFS. Secondary endpoints included OS and tumour extrahepatic recurrence rate (ERR). The Huaier (n=686) and control groups (n=316) had a mean RFS of 75.5 weeks and 68.5 weeks, respectively (HR 0.67; 95% CI 0.55 to 0.81). The difference in the RFS rate between Huaier and control groups was 62.39% and 49.05% (95% CI 6.74 to 19.94; p=0.0001); this led to an OS rate in the Huaier and control groups of 95.19% and 91.46%, respectively (95% CI 0.26 to 7.21; p=0.0207). The tumour ERR between Huaier and control groups was 8.60% and 13.61% (95% CI −12.59 to −2.50; p=0.0018), respectively. Conclusions This is the first nationwide multicentre study, involving 39 centres and 1044 patients, to prove the effectiveness of Huaier granule as adjuvant therapy for HCC after curative liver resection. It demonstrated a significant prolongation of RFS and reduced extrahepatic recurrence in Huaier group. Trial registration NCT01770431 ; Post-results.
Fractional Flow Reserve Derived From Computed Tomographic Angiography in Patients With Multivessel CAD
Authors: Carlos Collet, Yosuke Miyazaki, Nicola Ryan, Taku Asano, Erhan Tenekecioglu, Jeroen Sonck, Daniele Andreini, Manel Sabate, Salvatore Brugaletta, Rodney H. Stables, Antonio Bartorelli, Robbert J. de Winter, Yuki Katagiri, Ply Chichareon, Giovanni Luigi De Maria, Pannipa Suwannasom, Rafael Cavalcante, Hans Jonker, Marie-angèle Morel, Bernard Cosyns, Arie P. Kappetein, David T. Taggart, Vasim Farooq, Javier Escaned, Adrian Banning, Yoshinobu Onuma, Patrick W. Serruys
Journal: Journal of the American College of Cardiology (2018)
Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial
Authors: Toby M Maher, Ellen M van der Aar, Olivier Van de Steen, Lisa Allamassey, Julie Desrivot, Sonia Dupont, Liesbeth Fagard, Paul Ford, Ann Fieuw, Wim Wuyts
Journal: The Lancet Respiratory Medicine (2018)
The key role of kynurenine in antiPD-1 failure
Authors: Andrea Botticelli, Bruna Cerbelli, Luana Lionetto, Ilaria Zizzari, A Pisano, Michela Roberto, Concetta Elisa Onesti, Francesca Di Pietro, Chiara Napoletano, L Pizzuti, Patrizia Vici, Giulia D'Amati, Federica Mazzuca, Maurizio Simmaco, Patrizia Nuti, Paolo Marchetti
Journal: Cancer Research (2018)
Severe combined immunodeficiency in stimulator of interferon genes (STING) V154M/wild-type mice
Authors: Delphine Bouis, Peggy Kirstetter, Florent Arbogast, Delphine Lamon, Virginia Delgado, Sophie Jung, Claudine Ebel, Hugues Jacobs, Anne-Marie Knapp, Nadia Jeremiah, Alexandre Belot, Thierry Martin, Yanick J. Crow, Isabelle André-Schmutz, Anne-Sophie Korganow, Frédéric Rieux-Laucat, Pauline Soulas-Sprauel
Journal: Journal of Allergy and Clinical Immunology (2018)
Risk of Being Subjected to Crime, Including Violent Crime, After Onset of Mental Illness
Authors: Kimberlie Dean, Thomas M. Laursen, Carsten B. Pedersen, Roger T. Webb, Preben B. Mortensen, Esben Agerbo
Journal: JAMA Psychiatry (2018)

People with mental illness are more likely to have contact with the criminal justice system, but research to date has focused on risk of offense perpetration, while less is known about risk of being subjected to crime and violence.To establish the incidence of being subjected to all types of criminal offenses, and by violent crimes separately, after onset of mental illness across the full diagnostic spectrum compared with those in the population without mental illness.This investigation was a longitudinal national cohort study using register data in Denmark. Participants were a cohort of more than 2 million persons born between 1965 and 1998 and followed up from 2001 or from their 15th birthday until December 31, 2013. Analysis was undertaken from November 2016 until February 2018.Cohort members were followed up for onset of mental illness, recorded as first contact with outpatient or inpatient mental health services. Diagnoses across the full spectrum of psychiatric diagnoses were considered separately for men and women.Incidence rate ratios (IRRs) were estimated for first subjection to crime event (any crime and violent crime) reported to police after onset of mental illness. The IRRs were adjusted for cohort member's own criminal offending, in addition to several sociodemographic factors.In a total cohort of 2 058 063 (48.7% male; 51.3% female), the adjusted IRRs for being subjected to crime associated with any mental disorder were 1.49 (95% CI, 1.46-1.51) for men and 1.64 (95% CI, 1.61-1.66) for women. The IRRs were higher for being subjected to violent crime at 1.76 (95% CI, 1.72-1.80) for men and 2.72 (95% CI, 2.65-2.79) for women. The strongest associations were for persons diagnosed as having substance use disorders and personality disorders, but significant risk elevations were found across almost all diagnostic groups examined.Onset of mental illness is associated with increased risk of exposure to crime, and violent crime in particular. Elevated risk is not confined to specific diagnostic groups. Women with mental illness are especially vulnerable to being subjected to crime. Individual's own offending accounts for some but not all of the increased vulnerability to being subjected to crime.
Clinical efficacy and safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment in patients (pts) with ER+ and HER2- advanced breast cancer (ABC) who have not received any systemic treatment (ST): A subgroup analysis of PALOMA-1/TRIO-18.
Authors: Richard S. Finn, John Crown, Johannes Ettl, Tamas Pinter, Anu Thummala, Yaroslav V. Shparyk, Ravi Patel, Sophia Randolph, Sindy Kim, Xin Huang, Yuqiu Jiang, Cynthia Huang Bartlett, Dennis J. Slamon
Journal: Journal of Clinical Oncology (2015)

575 Background: P is an orally active inhibitor of CDK4/6. In a randomized phase II study, P + L significantly prolonged progression-free survival (PFS) vs L alone (20 vs 10 mo; HR = 0.488, P =0.0004; Finn et al, Lancet Oncol, 2015) in ER+/HER2- ABC as first-line treatment. Given that pts who did not receive any systemic treatment (ST) may have different disease biology/course from those treated and relapsed from early stage disease and many pts may initiate endocrine therapy (ET) alone, we investigated the benefit of P + L in this subgroup in the PALOMA-1/TRIO-18 study. Methods: 165 ER+ and HER2- postmenopausal pts who are treatment naïve for their ABC were randomized to receive L (N = 81) or P+L (N = 84). A subset of pts did not receive any ST in the adjuvant setting prior to randomization (P+L n = 44, L n = 37). The primary endpoint was investigator-assessed PFS. Tumor assessment was performed every 8 weeks. Tumor tissues were collected for correlative biomarkers. Results: Clinical characteristics at baseline were well balanced on median age (P+L vs. L: 63 vs 62), ECOG PS (0/1 59%/41% vs. 49%/51%) and site of disease (visceral/bone only/other: 55%/14%/32% vs. 51%/14%/35%). Observed mPFS was 24 m (95% CI 13, 35) for P+ L vs. 8 m for L (95% CI 6, 13) with HR = 0.315 (95% CI 0.175-0.566) (p < 0.0001). Overall response rate (ORR) was 48% (95% CI 33%, 63%) vs. 41% (25%, 58%); clinical benefit rate (PR+SD ≥ 24 wks) was 84% (70%, 93%) vs. 70% (53%, 84%). The most common treatment emerged adverse events (all grades) for P + L arm were neutropenia (67%), fatigue (49%), leucopenia (49%), and anemia (35%), consistent with the overall safety profile. Tissue samples were available in 73 pts. Loss of RB expression by immunohistochemistry was rare (5.4%). Ki67 baseline did not predict response. Conclusions: The addition of P to L increased by > 2 the PFS in pts who did not receive ST for their ER+ MBC. The most common AEs are manageable. Favorable risk benefit profile suggests P+L be considered for this group of pts. Clinical trial information: NCT00721409.
SHP-1 Acts as a Tumor Suppressor in Hepatocarcinogenesis and HCC Progression
Authors: Liang-Zhi Wen, Kai Ding, Ze-Rui Wang, Chen-Hong Ding, Shu-Juan Lei, Jin-Pei Liu, Chuan Yin, Ping-Fang Hu, Jin Ding, Wan-Sheng Chen, Xin Zhang, Wei-Fen Xie
Journal: Cancer Research (2018)

Abstract Src homology region 2 (SH2) domain–containing phosphatase 1 (SHP-1, also known as PTPN6) is a nonreceptor protein tyrosine phosphatase that acts as a negative regulator of inflammation. Emerging evidence indicates that SHP-1 plays a role in inhibiting the progression of hepatocellular carcinoma (HCC). However, the role of SHP-1 in hepatocarcinogenesis remains unknown. Here, we find that levels of SHP-1 are significantly downregulated in human HCC tissues compared with those in noncancerous tissues (P &amp;lt; 0.001) and inversely correlate with tumor diameters (r = −0.4130, P = 0.0002) and serum α-fetoprotein levels (P = 0.047). Reduced SHP-1 expression was associated with shorter overall survival of patients with HCC with HBV infection. Overexpression of SHP-1 suppressed proliferation, migration, invasion, and tumorigenicity of HCC cells, whereas knockdown of SHP-1 enhanced the malignant phenotype. Moreover, knockout of Ptpn6 in hepatocytes (Ptpn6HKO) enhanced hepatocarcinogenesis induced by diethylnitrosamine (DEN) as well as metastasis of primary liver cancer in mice. Furthermore, systemic delivery of SHP-1 by an adenovirus expression vector exerted a therapeutic effect in an orthotopic model of HCC in NOD/SCID mice and DEN-induced primary liver cancers in Ptpn6HKO mice. In addition, SHP-1 inhibited the activation of JAK/STAT, NF-κB, and AKT signaling pathways, but not the MAPK pathway in primary hepatocytes from DEN-treated mice and human HCC cells. Together, our data implicate SHP-1 as a tumor suppressor of hepatocarcinogenesis and HCC progression and propose it as a novel prognostic biomarker and therapeutic target of HCC. Significance: The nonreceptor protein tyrosine phosphatase SHP-1 acts as a tumor suppressor in hepatocellular carcinoma. Cancer Res; 78(16); 4680–91. ©2018 AACR.
Genotype–phenotype correlation of hereditary erythrocytosis mutations, a single center experience
Authors: Jennifer L. Oliveira, Lea M. Coon, Lori A. Frederick, Molly Hein, Kenneth C. Swanson, Michelle E. Savedra, Tavanna R. Porter, Mrinal M. Patnaik, Ayalew Tefferi, Animesh Pardanani, Stefan K. Grebe, David S. Viswanatha, James D. Hoyer
Journal: American Journal of Hematology (2018)

Hereditary erythrocytosis is associated with high oxygen affinity hemoglobin variants (HOAs), 2,3‐bisphosphoglycerate deficiency and abnormalities in EPOR and the oxygen‐sensing pathway proteins PHD, HIF2α, and VHL. Our laboratory has 40 years of experience with hemoglobin disorder testing and we have characterized HOAs using varied protein and molecular techniques including functional assessment by p50 analysis. In addition, we have more recently commenced adding the assessment of clinically relevant regions of the VHL , BPGM, EPOR , EGLN1 (PHD2), and EPAS1 (HIF2A) genes in a more comprehensive hereditary erythrocytosis panel of tests. Review of our experience confirms a wide spectrum of alterations associated with erythrocytosis which we have correlated with phenotypic and clinical features. Through generic hemoglobinopathy testing, we have identified 762 patients with 81 distinct HOA Hb variants (61 β, 20 α), including 12 that were first identified by our laboratory. Of the 1192 cases received for an evaluation specific for hereditary erythrocytosis, approximately 12% had reportable alterations: 85 pathogenic/likely pathogenic mutations and 58 variants of unknown significance. Many have not been previously reported. Correlation with clinical and phenotypic data supports an algorithmic approach to guide economical evaluation; although, testing is expanded if the suspected causes are negative or of uncertain significance. Clinical features are similar and range from asymptomatic to recurrent headaches, fatigue, restless legs, chest pain, exertional dyspnea and thrombotic episodes. Many patients were chronically phlebotomized with reported relief of symptoms.
Association of circulating CXCL10 and CXCL11 with systemic sclerosis
Authors: Clara Crescioli, Clarissa Corinaldesi, Valeria Riccieri, Valeria Raparelli, Massimiliano Vasile, Francesco Del Galdo, Guido Valesini, Andrea Lenzi, Stefania Basili, Cristina Antinozzi
Journal: Annals of the Rheumatic Diseases (2018)

Table 1 Demographic and clinical characteristics of patients with very early diagnosis of systemic sclerosis (VEDOSS) and systemic (SSc) (whose sera sample collection was used in the study).Characteristics SSc (n=28) VEDOSS (n=34) Age (years) 56.56±12.4550.50±13.66Male --Female 28 34 lcSSc subsets 25 (89%) -dcSSc subsets 3 (11%) -Disease duration (months) 91.3±11.7311.1±4.2ANA 26 (93%) 31 (91%) ACA 16 (57%) 17 (50%) Anti-topoisomerase I (Scl-70) 4 (14%) 5 (15%) Digital ulcers 4 (14%) -Normal NVC pattern 1 (4%) 13 (38%) Early NVC pattern 6 (21%) 11 (32%) Active NVC pattern 13 (46%) 9 (26%) Late NVC pattern 8 (29%) 1 (3%) Interstitial lung disease 6 (21%) -Age and disease duration were expressed as mean±SD/SE; disease duration was calculated since the first Raynaud phenomenon in VEDOSS and non-Raynaud symptom of SSc.Patients were not receiving corticosteroids, immunosuppressant or other disease-modifying drugs; patients with cardiac disease, pulmonary artery hypertension or active diseases other than SSc were excluded.Interstitial lung disease was determined by high-resolution computed tomography CT scan.ACA, anti-centromere antibodies;
Association of Optic Pathways and Brain Structure With Deep Brain Stimulation of the Nucleus Basalis of Meynert for Parkinson Disease Dementia—Reply
Authors: Thomas Foltynie, Marjan Jahanshahi, Marwan Hariz
Journal: JAMA Neurology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial
Authors: Pieter F. van der Meer, Paula F. Ypma, Nan van Geloven, Joost A. van Hilten, Rinie J. van Wordragen-Vlaswinkel, Okke Eissen, Jaap J. Zwaginga, Michael Trus, Erik A. M. Beckers, Peter te Boekhorst, Alan Tinmouth, Yulia Lin, Cyrus Hsia, David Lee, Philip J. Norris, Raymond P. Goodrich, Anneke Brand, Tor Hervig, Nancy M. Heddle, Johanna G. van der Bom, Jean-Louis H. Kerkhoffs
Journal: Blood (2018)
Adalimumab alleviates skin pain in patients with moderate-to-severe hidradenitis suppurativa: Secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials
Authors: Alexandra B. Kimball, Murali Sundaram, Alan L. Shields, Stacie Hudgens, Martin Okun, Catherine Foley, Arijit Ganguli
Journal: Journal of the American Academy of Dermatology (2018)
Abstract 11799: Silent Atrial Fibrillation in Pacemaker Early Post-implantation Period: An Unintentionally Provoked Situation?
Authors: Juan Benezet-Mazuecos, Jose Antonio Iglesias, Marcelino Cortes, Juan Jose de la Vieja, Jose Manuel Rubio, Pepa Sanchez-Borque, Angel Miracle, Jeronimo Farre
Journal: Circulation (2016)

Introduction: Identification of silent atrial fibrillation (AF) is crucial to avoid thromboembolic complications. Multiple studies have shown that atrial high rate episodes (AHREs) detected in pacemakers (PM) are related to an increased risk of stroke. Our group has also reported that AHREs are independently associated to a higher incidence of silent ischemic brain lesions (IBL) on CT-scan. Hypothesis: Our purpose is to evaluate the relation between AHREs and time from PM implantation / type of lead fixation used in patients with dual-chamber PM and no history of AF. AHREs soon after PM implantation might be related with the procedure itself and the prognosis could be different. Methods: We analyzed prospectively the incidence of AHREs &gt; 5 min compatible with silent AF (at 3 months after inclusion and during follow-up) and the presence of silent IBL, in relation to time from implantation (≤ 3 months vs. &gt;3 months) and the atrial lead fixation (active vs. passive). Results: We evaluated 110 consecutive patients (55% men, aged 74 ± 9 year-old) during a mean follow-up of 24 ± 8 months. Mean CHADS 2 and CHA 2 DS 2 VASc scores were 1.9 ± 1.2 and 3.5 ± 1.5, respectively. Time from PM implantation was ≤ 3 months in 88 patients (80%) and &gt; 3 months in 22 (20%). The type of fixation used was active in 55 patients and passive in other 55 (50%). AHREs were present in 40 patients (36.4%), 16 patients (14.5%) at first 3 months and 36 patients (32.7%) after. CT-scan showed silent IBL in 26 patients (23.6%). Table. The presence of AHREs at 3 months was more frequent in the patients with PM implantation in the prior 3 months (17% vs. 4.5%, p=0.09) and significantly related to active fixation leads (OR 5.36, 1.43 - 20.07; p&lt;0.05). The presence of silent IBL on CT-scan was related to the presence of AHREs during follow up (OR 3.12, 1.29 - 7.97; p&lt;0.05) but not with AHREs at first 3 months (OR 1.58, 0.49 - 5.05; p=0.44). Conclusions: AHREs compatible with silent AF are really prevalent in patients receiving PM and have been associated to worse outcomes including a higher incidence of silent IBL on CT-scan. But our data show that when AHREs occur during the first 3 months after PM implantation, it could be related with the procedure and the use of active fixation leads, and these episodes might not be related to worse outcomes.
Abstract 15477: Association Between TSH Levels and Hepatic Steatosis is Mediated by Metabolic Syndrome Factors
Authors: Carolina C Janovsky, Fernando H Cesena, Viviane A Tabone, Raquel D Conceição, Raul D Santos, Marcio S Bittencourt
Journal: Circulation (2017)

Introduction: Thyroid hormones are involved in the regulation of body composition, lipid metabolism and insulin resistance. Thus, they might play a role in the pathogenesis of non-alcoholic fatty l...
Do all daily metabolic equivalent task units (METs) bring the same health benefits?
Authors: Andreas Holtermann, Emmanuel Stamatakis
Journal: British Journal of Sports Medicine (2018)

In physical activity (PA) and exercise science, the prevailing view is that the health effect of PA is mainly determined by the accumulated rate of energy spent on PA over the day. Accordingly, generations of PA guidelines are based on the rate of energy spent during different tasks of PA, termed ‘metabolic equivalent tasks’ (abbreviated to ‘METs’) (see table 1). Accumulated daily METs (expressed in, for example, MET-hours or MET-minutes) are probably the most common in health-related measure of PA. But do daily METs really ‘tell the whole story’ of the health effects from PA?

View this table:

Table 1 
Examples of types of physical activities resulting in different categories of metabolic equivalent tasks (METs)



The report of the 2018 US Physical Activity Guidelines Advisory Committee1 represents the most up-to-date guidance on physical activity and health. Despite multiple novel elements, these guidelines encompass (eg, influence of PA on sleep and fatigue) the thinking that all METs are the same , no matter the context they are accrued in, still remains. But the evidence behind ‘the more daily METs—the better’ is generally …
Genetic Etiology for Alcohol-Induced Cardiac Toxicity
Authors: James S. Ware, Almudena Amor-Salamanca, Upasana Tayal, Risha Govind, Isabel Serrano, Joel Salazar-Mendiguchía, Jose Manuel García-Pinilla, Domingo A. Pascual-Figal, Julio Nuñez, Gonzalo Guzzo-Merello, Emiliano Gonzalez-Vioque, Alfredo Bardaji, Nicolas Manito, Miguel A. López-Garrido, Laura Padron-Barthe, Elizabeth Edwards, Nicola Whiffin, Roddy Walsh, Rachel J. Buchan, William Midwinter, Alicja Wilk, Sanjay Prasad, Antonis Pantazis, John Baski, Declan P. O’Regan, Luis Alonso-Pulpon, Stuart A. Cook, Enrique Lara-Pezzi, Paul J. Barton, Pablo Garcia-Pavia
Journal: Journal of the American College of Cardiology (2018)

Alcoholic cardiomyopathy (ACM) is defined by a dilated and impaired left ventricle due to chronic excess alcohol consumption. It is largely unknown which factors determine cardiac toxicity on exposure to alcohol. This study sought to evaluate the role of variation in cardiomyopathy-associated genes in the pathophysiology of ACM, and to examine the effects of alcohol intake and genotype on dilated cardiomyopathy (DCM) severity. The authors characterized 141 ACM cases, 716 DCM cases, and 445 healthy volunteers. The authors compared the prevalence of rare, protein-altering variants in 9 genes associated with inherited DCM. They evaluated the effect of genotype and alcohol consumption on phenotype in DCM. Variants in well-characterized DCM-causing genes were more prevalent in patients with ACM than control subjects (13.5% vs. 2.9%; p = 1.2 ×10−5), but similar between patients with ACM and DCM (19.4%; p = 0.12) and with a predominant burden of titin truncating variants (TTNtv) (9.9%). Separately, we identified an interaction between TTN genotype and excess alcohol consumption in a cohort of DCM patients not meeting ACM criteria. On multivariate analysis, DCM patients with a TTNtv who consumed excess alcohol had an 8.7% absolute reduction in ejection fraction (95% confidence interval: −2.3% to −15.1%; p < 0.007) compared with those without TTNtv and excess alcohol consumption. The presence of TTNtv did not predict phenotype, outcome, or functional recovery on treatment in ACM patients. TTNtv represent a prevalent genetic predisposition for ACM, and are also associated with a worse left ventricular ejection fraction in DCM patients who consume alcohol above recommended levels. Familial evaluation and genetic testing should be considered in patients presenting with ACM.